Common or street names: Magic Mushrooms, Mushrooms, Sacred Mushroom, Shrooms, Little Smoke, Purple Passion
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and psilocin are chemical compounds obtained from certain types of dried or fresh hallucinogenic mushrooms found in Mexico, South America and the southern and northwest regions of the United States. Psilocybin is classified as an indole-alkylamine (tryptamine). These compounds have similar structure to lysergic acid diethylamide (LSD), and are abused for their hallucinogenic and euphoric effects to produce a “trip”. Hallucinogenic (psychedelic) effects are probably due to action on central nervous system serotonin (5-HT) receptors.
There are over 180 species of mushrooms that contain the chemicals psilocybin or psilocin. Like the peyote (mescaline), hallucinogenic mushrooms have been used in native or religious rites for centuries. Both psilocybin and psilocin can also be produced synthetically in the lab. There have been reports that psilocybin bought on the streets can actually be other species of mushrooms laced with LSD.
“Magic Mushrooms” have long, slender stems which may appear white or greyish topped by caps with dark gills on the underside. Dried mushrooms are usually a reddish rust brown color with isolated areas of off-white. Mushrooms are ingested orally and may be made into a tea or mixed into other foods. The mushrooms may be used as fresh or dried product. Psilocybin has a bitter, unpalatable taste.
A “bad trip”, or a unpleasant or even terrifying experience, may occur with any dose of psilocybin. In general, dried mushrooms contain about 0.2% to 0.4% psilocybin and only trace amounts of psilocin. The typical dose of psilocybin used for recreational purposes varies, with peak effects occurring in 1 to 2 hours, and lasting for about six hours. Psilocybin
Dose and effects can vary considerably depending upon mushroom type, method of preparation, and tolerance of the individual. It can be difficult to determine the exact species of mushroom or how much hallucinogen each mushroom contains. Initial smaller doses and longer period of time to determine the effects may be a safer option if you choose to use psilocybin for recreational purposes.
Psilocybin effects are similar to those of other hallucinogens, such as mescaline from peyote or LSD. The psychological reaction to psilocybin use include visual and auditory hallucinations and an inability to discern fantasy from reality. Panic reactions and psychosis also may occur, particularly if large doses of psilocybin are ingested.
Hallucinogens that interfere with the action of the brain chemical serotonin may alter:
- sensory perception
- body temperature
- sexual behavior
- muscle control
Physical effects of psychedelic mushrooms may include a feeling of nausea, vomiting, muscle weakness, confusion, and a lack of coordination. Combined use with other substances, such as alcohol and marijuana can heighten, or worsen all of these effects.
Other effects of hallucinogenic drugs can include:
- intensified feelings and sensory experiences
- changes in sense of time (for example, time passing by slowly)
- increased blood pressure, breathing rate, or body temperature
- loss of appetite
- dry mouth
- sleep problems
- mixed senses (such as “seeing” sounds or “hearing” colors)
- spiritual experiences
- feelings of relaxation or detachment from self/environment
- uncoordinated movements
- lowered inhibition
- excessive sweating
- paranoia – extreme and unreasonable distrust of others
- psychosis – disordered thinking detached from reality
Larger psilocybin doses, including an overdose, can lead to intense hallucinogenic effects over a longer period of time. An intense “trip” episode may occur, which may involve panic, paranoia, psychosis, frightful visualizations (“bad trip”), and very rarely death. Memory of a “bad trip” can last a lifetime.
Abuse of psilocybin mushrooms could also lead to toxicity or death if a poisonous mushroom is incorrectly thought to be a “magic” mushroom and ingested. If vomiting, diarrhea, or stomach cramps begin several hours after consuming the mushrooms, the possibility of poisoning with toxic mushrooms should be considered, and emergency medical care should be sought immediately.
Tolerance to the use of psilocybin has been reported, which means a person needs an increasing larger dose to get the same hallucinogenic effect. “Flashbacks”, similar to those occur in some people after using LSD, have also been reported with mushrooms. It is reported that people who use LSD or mescaline can build a cross-tolerance to psilocybin, as well.
Common hallucinogens, with the possible exception of phencyclidine (PCP), are not usually tested for on standard workplace drug screens. However, if desired by legal authorities, medical personnel, or an employer, it is possible to perform laboratory assays that can detect any drug or metabolite, including psilocybin, via advanced laboratory techniques.
When tested via urine, the psilocybin mushroom metabolite psilocin can stay in your system for up to 3 days. However, metabolic rate, age, weight, age, medical conditions, drug tolerance, other drugs or medications used, and urine pH of each individual may affect actual detection periods.
Based on the 2020 survey from SAMHSA’s National Survey on Drug Use and Health (NSDUH), published in October 2021, about 7.1 million people aged 12 or older (2.6%) reported using hallucinogens in the year prior to the survey. In 2018, that number was roughly 5.6 million people.
In the survey, hallucinogens include not only psilocybin from mushrooms, but also other psychedelic drugs like LSD, PCP, peyote, mescaline, “Ecstasy” (MDMA or “Molly”), ketamine, DMT/AMT/“Foxy,” and Salvia divinorum. In comparison, 49.6 million people used marijuana in the year prior to the 2020 survey.
The percent of hallucinogen users among young adults aged 18 to 25 (7.3% or 2.4 million people) was higher than the percentages among adolescents aged 12 to 17 (1.5% or 370,000 people) or adults aged 26 or older (2% or 4.3 million people).
In a few states or cities, psilocybin is decriminalized with some restrictions. However, psilocybin is a Schedule I substance under federal law in the DEA’s Controlled Substances Act (CSA). The CSA states it is a substance with a high potential for abuse, no currently accepted medical use in treatment in the U.S., and a lack of accepted safety for use under medical supervision.
In November 2020, the state of Oregon passed Measure 109 to legalize psilocybin for people age 21 and older. In another vote, psilocybin was decriminalized. Proponents of psilocybin legalization in Oregon promote its use for medical conditions, such as depression, anxiety, or PTSD. The new law will make psilocybin more accessible to people who need them clinically. Measure 109 will be enacted after a developmental stage is completed, expected to be a two year process.
In the 2022 U.S. midterm elections, Colorado approved a ballot measure to decriminalize psilocybin and psilocin found in magic mushrooms for adults 21 years of age and older. It is restricted in Colorado, with clinical use eventually allowed at state-run “therapeutic” centers, under the supervision of licensed facilitators (expected in 2024). Personal use is legal, but retail sales are not permitted. Adults can grow, possess and share psilocybin but not sell it for personal use. Three related psychedelic compounds, DMT, ibogaine and mescaline, were also decriminalized (but not mescaline extracted from peyote).
Washington, DC also decriminalized psilocybin in Nov. 2020, and San Francisco, CA in 2022. At least a dozen other U.S. cities, including Oakland, CA, Denver, CO, Ann Arbor, MI, Seattle, WA and Cambridge, MA have also decriminalized psilocybin use to various degrees.
Federal law still considered psilocybin a Schedule I drug by the US Drug Enforcement Agency (DEA). Researchers may be able to get access to the compound to study its effects through special waivers from the U.S. Food and Drug Administration (FDA).
Other drugs found in federal Schedule I include marijuana, LSD, and heroin. In order for psilocybin to be prescribed for patients, it would have to be reclassified as a Schedule II medication, meaning it has a currently accepted medical use, but with severe restrictions due to addiction potential.
Although psilocybin has been used for centuries in rituals, modern medicine has recently reported clinical studies, as well. Studies have been completed evaluating its use in anxiety and fear in people with terminal cancer, serious depression, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), smoking cessation,
A report was published in the Journal of Psychopharmacology detailing two small studies that noted the ingredient in “magic mushrooms” – psilocybin – can reverse the feeling of “existential distress” that patients often feel after being treated for cancer. Reportedly, cancer can leave patients with this type of psychiatric disorder, feeling that life has no meaning. Typical treatments such as antidepressants may not be effective. However, use of a single dose of synthetic psilocybin reversed the distress felt by the patients and was a long-term effect. Some advanced cancer patients described the effect from the drug as if “the cloud of doom seemed to lift.”
Two additional studies using psilocybin were completed: one at New York University (NYU) Langone Medical Center in New York City and one at Johns Hopkins Medical School in Baltimore. For both studies, trained monitors were with patients as they experienced the effects of the drug, which can lead to hallucinations.
- In the NYU study, 29 patients with advanced cancer were given either a single dose of psilocybin or the B vitamin known as niacin, both in conjunction with psychotherapy. After seven weeks, the patients switched treatments (a cross-over study). In 60% to 80% of the patients receiving psilocybin, a relief from distress occurred rapidly and lasted over six months. The long-term effect was evaluated by researchers looking at test scores for depression and anxiety.
- In the Johns Hopkins study, researchers treated 51 adults with advanced cancer with a small dose of psilocybin followed five weeks later with a higher dose, with a 6-month follow-up. As with the NYU study, about 80% of participants experienced clinically significant relief from their anxiety and depression that lasted up to six months.
At the Center for Psychedelic and Consciousness Research at Johns Hopkins University in Baltimore, Maryland, researchers are focusing on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. This research group was the first to obtain U.S. regulatory approval to continue research with psychedelics in healthy volunteers.
As reported by Johns Hopkins, studies are evaluating the use of psilocybin as a new therapy for opioid addiction, Alzheimer’s disease, treatment-resistant depression, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), smoking cessation, anorexia nervosa and alcohol use disorder. A focus on precision medicine tailored to the individual patient is expected.
Additional studies with psilocybin are expected, and one is comparing the chemical against a leading traditional antidepressant. In many studies, psilocybin is used as a single dose treatment, with long-term effects.
In November 2019, the FDA designated psilocybin therapy as a “breakthrough therapy” for depression to the Usona Institute, an action the agency uses to speed up development and review of investigational drugs. Breakthrough therapies are expected to provide a major improvement over currently available agents for an unmet medical need.
Usona’s PSIL201 psilocybin U.S. clinical trial is a Phase 2 study evaluating psilocybin as a treatment for Major Depressive Disorder (MDD). This research will use a randomized, double-blind, placebo-controlled study design to measure the antidepressant effects of a single dose of psilocybin in 80 patients between 21 to 65 years of age with MDD. According to the manufacturer, “psilocybin potentially offers a novel paradigm in which a short-acting compound imparts profound alterations in consciousness and could enable long-term remission of depressive symptoms.”
If FDA-approved, psilocybin would have to be reclassified by the DEA for it to be available for patients; it is currently classified as a Schedule I drug.